FINANCIAL CHRONICLE™
Dear Reader,

Registration with the Sri Lanka FINANCIAL CHRONICLE™️ would enable you to enjoy an array of other services such as Member Rankings, User Groups, Own Posts & Profile, Exclusive Research, Live Chat Box etc..

All information contained in this forum is subject to Disclaimer Notice published.


Thank You
FINANCIAL CHRONICLE™️
www.srilankachronicle.com


Join the forum, it's quick and easy

FINANCIAL CHRONICLE™
Dear Reader,

Registration with the Sri Lanka FINANCIAL CHRONICLE™️ would enable you to enjoy an array of other services such as Member Rankings, User Groups, Own Posts & Profile, Exclusive Research, Live Chat Box etc..

All information contained in this forum is subject to Disclaimer Notice published.


Thank You
FINANCIAL CHRONICLE™️
www.srilankachronicle.com
FINANCIAL CHRONICLE™
Would you like to react to this message? Create an account in a few clicks or log in to continue.
FINANCIAL CHRONICLE™

Encyclopedia of Latest news, reviews, discussions and analysis of stock market and investment opportunities in Sri Lanka

LISTED COMPANIES

Submit Post



Poll

Can there be another Covid-19 wave in Sri Lanka?

Cancer drug success cuts short clinical trial Vote_lcap68%Cancer drug success cuts short clinical trial Vote_rcap 68% [ 178 ]
Cancer drug success cuts short clinical trial Vote_lcap18%Cancer drug success cuts short clinical trial Vote_rcap 18% [ 47 ]
Cancer drug success cuts short clinical trial Vote_lcap13%Cancer drug success cuts short clinical trial Vote_rcap 13% [ 35 ]

Total Votes : 260

STOCK MARKET TRAINING
ශ්‍රී ලංකා මූල්‍ය වංශකථාව - සිංහල
Submit Post


CONATCT US


Send your suggestions and comments

* - required fields

Read FINANCIAL CHRONICLE™ Disclaimer



Latest topics

» ACCESS ENGINEERING PLC (AEL.N0000)
by C.THARANGA Today at 12:38 am

» EXPOLANKA HOLDINGS PLC (EXPO.N0000)
by Captain Yesterday at 11:12 pm

» EXPO/BILL/LOLC
by Stockbull Yesterday at 9:39 pm

» EDEN HOTEL LANKA PLC (EDEN.N0000)
by Stockbull Yesterday at 2:06 pm

» The fate of NIFL .. CLC .. LOFC under LOCH
by svkiruba8@gmail.com Yesterday at 1:39 pm

» LOFC AND CLC Target Price??
by svkiruba8@gmail.com Yesterday at 1:36 pm

» Bitcoin could trigger financial meltdown, warns Bank of England deputy
by Sunimal Yesterday at 10:21 am

» VFIN super performance
by chandike73 Fri Oct 22, 2021 6:03 pm

» Today is the Best - Day to buy CLC ..!
by Sapudev Fri Oct 22, 2021 5:45 pm

» Thoughts on SINS
by Bakka1988 Fri Oct 22, 2021 2:52 pm

» LGL.N_UPDATES
by thananjey Fri Oct 22, 2021 2:43 pm

» Rubber prices hit 4-month high; here are key driving factors
by ResearchMan Fri Oct 22, 2021 2:13 pm

» Lubricant oil Prices increases for third time.. Keep eye on Industry
by rukshan1234 Fri Oct 22, 2021 1:40 pm

» Bad news, bulls: Bank of America sees stocks flatlining through 2022
by ResearchMan Fri Oct 22, 2021 1:28 pm

» Dusit Thani Sri Lanka project halted?
by js71 Fri Oct 22, 2021 12:59 pm

» China-US freight rates plunge
by ResearchMan Fri Oct 22, 2021 12:16 pm

» Europe Gas: Prices fall as drop in coal markets offsets higher demand
by ResearchMan Fri Oct 22, 2021 12:13 pm

» Maharaja after long time
by Wickyz Fri Oct 22, 2021 11:59 am

» SUNSHINE HOLDINGS PLC (SUN.N0000)
by Wickyz Fri Oct 22, 2021 11:50 am

» LOLC gets balance $ 225 m from Cambodia PRASAC stake sale
by stockchaser Fri Oct 22, 2021 10:45 am

EXPERT CHRONICLE™

MARKET CHAT


CHRONICLE™ ANALYTICS


ECONOMIC CHRONICLE

GROSS DOMESTIC PRODUCT (GDP)


CHRONICLE™ YouTube

LATEST TWEETS

You are not connected. Please login or register

FINANCIAL CHRONICLE™ » FUN CHRONICLE™ » Cancer drug success cuts short clinical trial

Cancer drug success cuts short clinical trial

Go down  Message [Page 1 of 1]

mission


Manager - Equity Analytics
Manager - Equity Analytics
Advanced prostate cancer drug improved survival

Mon 26 Sep, 2011 12:00 am BST

A prostate cancer drug trial has been stopped early, because the treatment was found to be so effective.

Doctors at the Royal Marsden Hospital cut short the phase III clinical trial of the drug - Radium 233 chloride - in patients with advanced prostate cancer, after they found that it significantly improved overall patient survival.

"It would have been unethical not to offer the active treatment to those taking placebo," Dr Chris Parker, a clinical oncologist, told the European Multidisciplinary Cancer Congress in Stockholm.

The drug, also known as Alpharadin - is a type of alpha-pharmaceutical which works by delivering minute quantities of damaging alpha radiation to secondary cancer cells in the bone.

The researchers decided to test Alpharadin in prostate cancer patients, as the disease spreads to the bone in nine out of ten men with the advanced form of the disease.

Radium also sticks to bone, the researchers said, especially new bone that is being made, which makes it 'highly effective' at delivering radiation to target cancer cells.

"It takes only a single alpha particle to kill a cell," said Dr Parker explained, "and collateral damage is minimised because the particles have such a tiny range - a few millionths of a metre (micrometres).

"So we can be sure that the damage is being done where it should be, to the metastasis, and very limited elsewhere."

The study involved 922 men with advanced prostate cancer. In all cases, the cancer had also spread to the patients' bones.

The patients received either standard treatment or Alpharadin plus standard treatment.

The study found that patients taking standard treatment plus Alpharadin had a 30 per cent lower rate of death compared to patients receiving standard treatment and a placebo (dummy drug).

Overall, the drug extended patient survival from around 11 months to 14 months.

Side-effects were reported to be minor, and included nausea, occasional diarrhoea and a 'very small effect on the bone marrow.'

"Although it has never been rigorously compared with chemotherapy, from observing patients in the clinic it is clear that patients tolerate it much better than they do chemotherapy," Dr Parker said.

The researchers now intend to submit the findings for regulatory approval.

"I would hope that the authorities will approve radium-223 as a treatment for bone metastases in advanced prostate cancer soon," said Dr Parker.

"Additionally, the drug could be used in many other types of cancers which metastasise to bone, regardless of the primary site. We believe that our trial may have paved the way for improvements in survival for very many cancer patients."

http://uk.health.lifestyle.yahoo.net/prostate-cancer-drug-success-halts-trial.htm

Back to top  Message [Page 1 of 1]

Permissions in this forum:
You cannot reply to topics in this forum